More recently, targeted therapy (e.g. BRAF-inhibitors) and immunotherapy (e.g. anti CTLA-4 and anti-PD-1 antibodies) have greatly influenced the management of (metastatic) cutaneous melanoma. Here, BRAF is linked to cutaneous melanoma.